F. Hoffmann-La Roche Ltd, PerkinElmer Inc. and Illumina, Inc. are dominating the Global Down Syndrome Market in 2020

Global Down Syndrome Market is expected to grow with the CAGR of 14.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-down-syndrome-market

Global Down syndrome market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global Down syndrome market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance:  

F. Hoffmann-La Roche renewed its partnership with Sysmex to deliver haematology testing solutions on January, 2021.

F. Hoffmann-La Roche Ltd is the dominating player in global Down syndrome market. The other key players existing in the market are Natera, Inc., Next Biosciences, AtilaBiosystems, Myriad Genetics, Inc., PerkinElmer Inc., Demeditec Diagnostics GmbH, Thermo Fisher Scientific Inc., Abnova Corporation, Novus Biologicals (a subsidiary of Bio-Techne, Mayo Clinic Health System, Boys Town National Research Hospital, Boston Children's Hospital, Kid Sense Child Development Corporation Pty Ltd, Down Syndrome Cork , a branch of Down Syndrome Ireland, Children's Hospital Colorado, ASDclinic.co.uk, Symbol, Abbott, Physio.co.uk., Illumina, Inc. and others.

Down Syndrome MarketF. Hoffmann-La Roche

The company was founded in the year 1896 and its headquarters is in Basel, Switzerland. The company is a pioneer in healthcare the healthcare industry. F. Hoffmann-La Roche is a front-runner in personalised healthcare, a global leader in cancer treatments and provides in vitro diagnostics Moreover, company is a committed investor in innovations. The company has business segments includes human therapeutics. The company has wide product categories such as in pharmaceuticals, diagnostics and research categories.

For instance,

  • In January 2021, Roche’s faricimab met primary endpoint in two global phase III studies and showed potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration.

The company has wide presence across North America, Europe, Asia-Pacific and Rest of the world.

PerkinElmer Inc.

PerkinElmer Inc. headquarters is in Massachusetts, United States. PerkinElmer Inc. was founded in the year 1937. The company provides products and is focused in areas such as industrial testing, environmental, food, life-science research, diagnostics, analytical instruments, cord blood banking and others.

For instance,

  • In January 2021, PerkinElmer Inc. invested in Carterra for antibody screening and characterization who has the expertise in label-free high throughput antibody screening and characterization, announced that they have closed on a round of equity financing led by PerkinElmer.

The company has presence across Asia Pacific, Europe, Middle East, North America, and Latin America. The company also has various subsidiary companies such as PerkinElmer Health Sciences, Inc., NTD Laboratories, Inc., PerkinElmer Sciex Instruments, PerkinElmer Chile Ltda,

PerkinElmer Danmark A/S, PerkinElmer Finland Oy and others.

 Illumina, Inc. 

Illumina, Inc. is a public company founded in 1998 and has its headquarters in California, the United States. The company markets, manufactures and develops integrated systems for analysis of biological function and genetic variation. The company provides products in proteomics market, genomics expressions, genotyping and sequencing. Some of the products include HiSeq X, MiSeq, iScan and others.

For instance,

  • In January 2021, Illumina collaborated with Bristol Myers Squibb to expand global collaboration for enhancing and innovating companion diagnostics for the section of therapyto further precision oncology.

The company has presence in North America and Others.